ALL-I-0143

What is Inflammatory Bowel Disease?

Crohn’s Disease and Ulcerative Colitis are the two most common types of Inflammatory Bowel Disease (IBD), a blanket term for conditions that cause inflammation in the digestive tract. Most cases of IBD present with the same set of symptoms, abdominal pain, diarrhea, cramps, weight loss and rectal bleeding. IBD affects a little over one percent (1%) of the population and carries a significant hospitalization cost as well as a detrimental effect on overall quality of life. Individuals who are diagnosed with IBD are more likely to develop a number of health conditions including liver diseases, kidney disease, arthritis, cancer, and cardiovascular disease.

Mode of Action

ALL-I-0143 is a bispecific nanoantibody drug that contains three tumor necrosis factor alpha (TNFα) binding modules. TNFα is a key protein involved in promoting systemic inflammation. Inhibition of TNFα has shown an immunosuppresive effect in addition to an overall reduction in inflammation.

Back to list -->